JA
Insider
Jeffrey W. Albers
DirectorJeffrey W. Albers (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in BPMC. The largest single filing was $2.4M of SYRE (23,000 sh across 3 lots, as filed), executed Aug 7. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.9M
shares × price, as filed
Last traded
Aug 7
Filed Aug 10
Median ADV $118.2M across their filed names
Open performance→Volume by month
Buys $0
Sells $8.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
BPMC
BPMC
0 buys · 7 sells
7 filings
KYMRRecent filings
BPMCSALE
Blueprint Medicines Corp
View filing →
$511K5,000 sh × $102.28
Exec Jan 13 2025
Filed Jan 15 2025 · 5:30 PM ET BPMCSALE Blueprint Medicines Corp View filing → $1.3M
15,000 sh across 4 lots
Exec Dec 19 2024
Filed Dec 20 2024 · 5:30 PM ET BPMCSALE Blueprint Medicines Corp View filing → $510K
5,000 sh × $102.00
Exec Nov 7 2024
Filed Nov 12 2024 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $246K
6,700 sh × $36.76
Exec Nov 6 2024
Filed Nov 8 2024 · 5:30 PM ET